Pembrolizumab-Induced Autoimmune Encephalitis in Triple-Negative Breast Cancer
Author Information
Author(s): Muacevic Alexander, Adler John R, Modi Shivani K, Bhimineni Charishma, Rathod Malay, Palaferro Danielle, Dhamankar Minal
Primary Institution: Einstein Medical Center Montgomery
Conclusion
The patient's symptoms of expressive aphasia resolved rapidly after stopping pembrolizumab and starting high-dose steroids.
Supporting Evidence
- The patient developed expressive aphasia three days after starting pembrolizumab.
- Comprehensive evaluations ruled out infectious or metastatic causes.
- Symptoms improved significantly after discontinuing immune checkpoint inhibitors and starting high-dose corticosteroids.
Takeaway
A woman with breast cancer had trouble speaking after starting a new cancer treatment, but she got better quickly after doctors changed her medicine and gave her steroids.
Methodology
The case report details the patient's symptoms, diagnostic evaluations, and treatment plan.
Limitations
The study is based on a single case report, limiting generalizability.
Participant Demographics
41-year-old female with stage IIIc triple-negative breast cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website